<p>2025 年 2 月 5 日- 上午 11:05</p>
<p><strong>Cosmos Health Inc.</strong> <strong>（&#34;Cosmos Health&#34;或&#34;公司&#34;）</strong> <strong>（NASDAQ:COSM）</strong> 是一家多元化、垂直整合的全球医疗保健集团，专注于创新研发，拥有专有的制药和营养保健品牌，制造和分销医疗产品，并运营远程医疗平台，今天宣布已提交多发性硬化症（MS）的专利申请，这是一种影响全球数百万人的致残性自身免疫疾病。</p>
<p>该专利申请以申请编号 <strong>N2039644</strong> 提交，代表了公司知识产权战略的重要进展。这一里程碑突显了 Cosmos Health 与 Cloudpharm 和希腊国家研究基金会的战略合作关系，并得到了 NLO 制药专利专家团队的支持。</p>
<p>该专利得到了基于数据的计算机模拟证据的支持，这些模拟由 Cosmos Health 的人工智能驱动的 Cloudscreen 药物再利用平台生成，并进行了强有力的实验验证。Cosmos Health 的最新研究结果表明，一种已上市药物在治疗 MS 方面具有潜力，发明者识别出了一种独特的作用机制。</p>
<p>这些进展强调了公司致力于应对自身免疫疾病挑战并提供创新解决方案以改善患者护理的承诺。</p>
<p><strong>多发性硬化症</strong></p>
<p>多发性硬化症是一种慢性自身免疫疾病，影响中枢神经系统，导致广泛的症状和显著的残疾。根据《多发性硬化症地图》，全球生活在 MS 患者中的人数从 2013 年的 230 万上升到 2023 年的 290 万。由于其不可预测的进展，MS 给患者和医疗提供者带来了持续的挑战。</p>
<p><strong>全球市场概述</strong></p>
<p>根据 Grand View Research 的报告，全球多发性硬化症治疗市场正在稳步增长，推动因素包括治疗选择的进步和疾病的日益普遍。该市场在 2023 年的估值约为 259.4 亿美元，预计在 2024 年至 2030 年期间将以 5.9% 的年复合增长率（CAGR）增长。这一增长得益于创新疗法的推出、医疗投资的增加以及针对 MS 患者未满足需求的持续研究。</p>
<p><strong>Cosmos Health 首席执行官 Greg Siokas 表示：</strong> &#34;这项专利申请是我们知识产权组合中的另一个重要补充，反映了我们致力于推动复杂疾病创新治疗的决心。通过关注多发性硬化症，我们正在解决一个关键的医疗需求，并致力于为全球患者提供有影响力的解决方案。&#34;</p>
<p><strong>关于 Cosmos Health Inc.</strong></p>
<p>Cosmos Health Inc.（Nasdaq:COSM）成立于 2009 年，注册于内华达州，是一家多元化、垂直整合的全球医疗保健集团。公司拥有一系列专有的制药和营养保健品牌，包括 Sky Premium Life®、Mediterranation®、bio-bebe®、C-Sept®和 C-Scrub®。通过其子公司 Cana Laboratories S.A.，该公司在欧洲良好生产规范（GMP）下获得许可，并获得欧洲药品管理局（EMA）的认证，在欧盟内制造药品、食品补充剂、化妆品、杀生物剂和医疗器械。Cosmos Health 还通过其在希腊和英国的子公司向零售药店和批发分销商分销广泛的药品和非处方药，包括品牌仿制药和 OTC 药物。此外，公司已建立针对肥胖、糖尿病和癌症等重大健康问题的研发合作关系，借助人工智能药物再利用技术，专注于新型专利营养保健品、专门根提取物、专有复合仿制药和创新 OTC 产品的研发。Cosmos Health 还通过收购位于美国德克萨斯州的 ZipDoctor, Inc.进入了远程医疗领域。凭借全球分销平台，公司目前正在欧洲、亚洲和北美扩展，并在希腊的塞萨洛尼基和雅典以及英国的哈洛设有办事处和分销中心。更多信息请访问 www.cosmoshealthinc.com、www.skypremiumlife.com、www.cana.gr、www.zipdoctor.co、www.cloudscreen.gr，以及 LinkedIn 和 X。</p>
<p><strong>前瞻性声明</strong></p>
<p>除本新闻稿中包含的历史信息外，此处描述的事项可能包含根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的修订版的前瞻性声明。以 “相信”、“期望”、“预期”、“打算”、“项目”、“估计”、“计划” 等词语开头、结尾或以其他方式包含这些词语的声明，以及 “将”、“应该”、“会”、“可能” 和 “能够” 等未来或条件动词，通常具有前瞻性特征，而非历史事实，尽管并非所有前瞻性声明都包含上述内容。这些声明涉及未知的风险和不确定性，可能会因多种原因对此处讨论的事项产生单独或重大影响，这些原因超出了公司的控制范围，包括但不限于公司筹集足够资金以实施其商业计划的能力、COVID-19 大流行和乌克兰战争对公司业务、运营及整体经济的影响，以及公司成功开发和商业化其专有产品和技术的能力。读者应谨慎对待这些前瞻性声明，不应过度依赖，因为实际结果可能与此处包含的前瞻性声明所描述的结果有重大差异。读者被敦促阅读公司向美国证券交易委员会（SEC）提交的风险因素，这些文件可在 SEC 网站（www.sec.gov）上获取。公司不承担更新或修订任何前瞻性声明的意图或义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>投资者关系联系方式：</strong></p>
<p>BDG Communications</p>
<p>cosm@bdgcommunications.com</p>
<p>+44 207 0971 653</p>
<p><strong>来源：</strong> Cosmos Health Inc.</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9OTgwMDUy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9OTgwMDUy"/></p>

COSM

<p>Cosmos Health Inc. 已提交一项针对多发性硬化症的新治疗方法的专利申请，目标是一个价值超过 250 亿美元的全球市场。该申请得到了基于人工智能的数据支持，并与 Cloudpharm 和希腊国家研究基金会的合作，标志着公司知识产权战略的重要一步。全球多发性硬化症治疗市场预计将在 2024 年至 2030 年间以 5.9% 的年均增长率增长，推动因素包括疗法的进步和疾病的日益普遍。首席执行官 Greg Siokas 强调了公司对复杂疾病创新解决方案的承诺</p>

<p>02/05/2025 - 11:05 AM</p>
<div class="lb-trans"><p>2025 年 2 月 5 日- 上午 11:05</p>
</div><p><strong>Cosmos Health Inc.</strong> <strong>(&#34;Cosmos Health&#34; or the &#34;Company&#34;)</strong> <strong>(NASDAQ:COSM)</strong>, a diversified, vertically integrated global healthcare group engaged in innovative R&amp;D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of a patent application for multiple sclerosis (MS), a disabling autoimmune disorder affecting millions worldwide.</p>
<div class="lb-trans"><p><strong>Cosmos Health Inc.</strong> <strong>（&#34;Cosmos Health&#34;或&#34;公司&#34;）</strong> <strong>（NASDAQ:COSM）</strong> 是一家多元化、垂直整合的全球医疗保健集团，专注于创新研发，拥有专有的制药和营养保健品牌，制造和分销医疗产品，并运营远程医疗平台，今天宣布已提交多发性硬化症（MS）的专利申请，这是一种影响全球数百万人的致残性自身免疫疾病。</p>
</div><p>The patent application, filed under Application Number <strong>N2039644</strong>, represents a significant step forward in the Company's intellectual property strategy. This milestone highlights Cosmos Health's strategic partnership with Cloudpharm and the National Hellenic Research Foundation, supported by the pharma patent expert team at NLO.</p>
<div class="lb-trans"><p>该专利申请以申请编号 <strong>N2039644</strong> 提交，代表了公司知识产权战略的重要进展。这一里程碑突显了 Cosmos Health 与 Cloudpharm 和希腊国家研究基金会的战略合作关系，并得到了 NLO 制药专利专家团队的支持。</p>
</div><p>The patent is supported by data-driven in silico evidence and simulations generated by Cosmos Health's AI-powered Cloudscreen drug repurposing platform, coupled with robust experimental validation. Recent findings by Cosmos Health have demonstrated the potential of a repurposed marketed drug for treating MS, with the inventors identifying a unique mechanism of action.</p>
<div class="lb-trans"><p>该专利得到了基于数据的计算机模拟证据的支持，这些模拟由 Cosmos Health 的人工智能驱动的 Cloudscreen 药物再利用平台生成，并进行了强有力的实验验证。Cosmos Health 的最新研究结果表明，一种已上市药物在治疗 MS 方面具有潜力，发明者识别出了一种独特的作用机制。</p>
</div><p>These advancements underscore the Company's commitment to tackling the challenges of autoimmune diseases and providing innovative solutions to enhance patient care.</p>
<div class="lb-trans"><p>这些进展强调了公司致力于应对自身免疫疾病挑战并提供创新解决方案以改善患者护理的承诺。</p>
</div><p><strong>Multiple Sclerosis</strong></p>
<div class="lb-trans"><p><strong>多发性硬化症</strong></p>
</div><p>Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, causing a wide range of symptoms and significant disability. According to the Atlas of MS, the number of individuals living with MS globally has risen from 2.3 million in 2013 to 2.9 million in 2023. With its unpredictable progression, MS presents ongoing challenges for patients and healthcare providers alike.</p>
<div class="lb-trans"><p>多发性硬化症是一种慢性自身免疫疾病，影响中枢神经系统，导致广泛的症状和显著的残疾。根据《多发性硬化症地图》，全球生活在 MS 患者中的人数从 2013 年的 230 万上升到 2023 年的 290 万。由于其不可预测的进展，MS 给患者和医疗提供者带来了持续的挑战。</p>
</div><p><strong>Global Market Overview</strong></p>
<div class="lb-trans"><p><strong>全球市场概述</strong></p>
</div><p>According to Grand View Research, the global multiple sclerosis treatment market has been experiencing steady growth, driven by advancements in therapeutic options and a rising prevalence of the disease. The market was valued at approximately $25.94 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2030. This growth is fueled by the introduction of innovative therapies, increased healthcare investments, and ongoing research to address the unmet needs of MS patients.</p>
<div class="lb-trans"><p>根据 Grand View Research 的报告，全球多发性硬化症治疗市场正在稳步增长，推动因素包括治疗选择的进步和疾病的日益普遍。该市场在 2023 年的估值约为 259.4 亿美元，预计在 2024 年至 2030 年期间将以 5.9% 的年复合增长率（CAGR）增长。这一增长得益于创新疗法的推出、医疗投资的增加以及针对 MS 患者未满足需求的持续研究。</p>
</div><p><strong>Greg Siokas, CEO of Cosmos Health, stated:</strong> &#34;This patent application is another important addition to our intellectual property portfolio and reflects our dedication to advancing innovative treatments for complex diseases. By focusing on multiple sclerosis, we are addressing a critical medical need and are committed to delivering impactful solutions for patients worldwide.&#34;</p>
<div class="lb-trans"><p><strong>Cosmos Health 首席执行官 Greg Siokas 表示：</strong> &#34;这项专利申请是我们知识产权组合中的另一个重要补充，反映了我们致力于推动复杂疾病创新治疗的决心。通过关注多发性硬化症，我们正在解决一个关键的医疗需求，并致力于为全球患者提供有影响力的解决方案。&#34;</p>
</div><p><strong>About Cosmos Health Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Cosmos Health Inc.</strong></p>
</div><p>Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&amp;D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&amp;D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.</p>
<div class="lb-trans"><p>Cosmos Health Inc.（Nasdaq:COSM）成立于 2009 年，注册于内华达州，是一家多元化、垂直整合的全球医疗保健集团。公司拥有一系列专有的制药和营养保健品牌，包括 Sky Premium Life®、Mediterranation®、bio-bebe®、C-Sept®和 C-Scrub®。通过其子公司 Cana Laboratories S.A.，该公司在欧洲良好生产规范（GMP）下获得许可，并获得欧洲药品管理局（EMA）的认证，在欧盟内制造药品、食品补充剂、化妆品、杀生物剂和医疗器械。Cosmos Health 还通过其在希腊和英国的子公司向零售药店和批发分销商分销广泛的药品和非处方药，包括品牌仿制药和 OTC 药物。此外，公司已建立针对肥胖、糖尿病和癌症等重大健康问题的研发合作关系，借助人工智能药物再利用技术，专注于新型专利营养保健品、专门根提取物、专有复合仿制药和创新 OTC 产品的研发。Cosmos Health 还通过收购位于美国德克萨斯州的 ZipDoctor, Inc.进入了远程医疗领域。凭借全球分销平台，公司目前正在欧洲、亚洲和北美扩展，并在希腊的塞萨洛尼基和雅典以及英国的哈洛设有办事处和分销中心。更多信息请访问 www.cosmoshealthinc.com、www.skypremiumlife.com、www.cana.gr、www.zipdoctor.co、www.cloudscreen.gr，以及 LinkedIn 和 X。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words &#34;believes,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;intends,&#34; &#34;projects,&#34; &#34;estimates,&#34; &#34;plans&#34; and similar expressions or future or conditional verbs such as &#34;will,&#34; &#34;should,&#34; &#34;would,&#34; &#34;may&#34; and &#34;could&#34;, are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>除本新闻稿中包含的历史信息外，此处描述的事项可能包含根据《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的修订版的前瞻性声明。以 “相信”、“期望”、“预期”、“打算”、“项目”、“估计”、“计划” 等词语开头、结尾或以其他方式包含这些词语的声明，以及 “将”、“应该”、“会”、“可能” 和 “能够” 等未来或条件动词，通常具有前瞻性特征，而非历史事实，尽管并非所有前瞻性声明都包含上述内容。这些声明涉及未知的风险和不确定性，可能会因多种原因对此处讨论的事项产生单独或重大影响，这些原因超出了公司的控制范围，包括但不限于公司筹集足够资金以实施其商业计划的能力、COVID-19 大流行和乌克兰战争对公司业务、运营及整体经济的影响，以及公司成功开发和商业化其专有产品和技术的能力。读者应谨慎对待这些前瞻性声明，不应过度依赖，因为实际结果可能与此处包含的前瞻性声明所描述的结果有重大差异。读者被敦促阅读公司向美国证券交易委员会（SEC）提交的风险因素，这些文件可在 SEC 网站（www.sec.gov）上获取。公司不承担更新或修订任何前瞻性声明的意图或义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系方式：</strong></p>
</div><p>BDG Communications</p>
<div class="lb-trans"><p>BDG Communications</p>
</div><p>cosm@bdgcommunications.com</p>
<div class="lb-trans"><p>cosm@bdgcommunications.com</p>
</div><p>+44 207 0971 653</p>
<div class="lb-trans"><p>+44 207 0971 653</p>
</div><p><strong>SOURCE:</strong> Cosmos Health Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Cosmos Health Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9OTgwMDUy" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=980052"/></p>

Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market | COSM Stock News

StockTitan

Cosmos Health 提交了新的 AI 驱动的多发性硬化症治疗专利申请，目标是 250 亿美元以上的全球市场 | COSM 股票新闻